Akihiro Yasoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akihiro Yasoda has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Kazuwa Nakao
15 shared publicationsHiroshi Arai
6 shared publicationsMasako Miura
6 shared publicationsEri Kondo
Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogo-in, Sakyo-ku, Kyoto 606-8507, Japan
5 shared publicationsNaotetsu Kanamoto
5 shared publicationsToshihito Fujii
Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogo-in, Sakyo-ku, Kyoto 606-8507, Japan
5 shared publications
Latest Publications
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
A case report: FGF23-related tumor-induced osteomalacia in a patient with pulmonary adenocarcinoma
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by the abnormal production of fibroblast growth factor 23 (FGF23) in the tumor. Here we report a case of TIO with pulmonary adenocarcinoma. A 61-year old woman was referred to our hospital. She was suffering from severe polyarthralgia and bilateral limb weakness. Her blood chemistry revealed high alkaline phosphatase, low phosphate, low calcium, and low 1,25-(OH)2D3. Bone-scintigraphy revealed multiple accumulations in femoral neck, sacrum, 1st rib, sacroiliac joints and many other joints, suggesting small fractures and systemic arthritis. Endocrinological analyses exhibited elevated iPTH and markedly high FGF23 level of 3900 pg/ml (reference: 14.7–40.5 pg/ml). These findings suggest that the FGF23-producing tumor of uncertain location induced osteomalacia in this patient. DOTATOC-PET/CT showed a major uptake in a nodular lesion of the left lung and several minor uptakes in the supraclavicular, hilar and mediastinal lymph nodes. An ultrasound-guided fine needle aspiration biopsy of the left supraclavicular lymph node was performed and the histological diagnosis was metastatic adenocarcinoma. PNA-LNA PCR clamp analysis of the biopsy specimen detected a mutation in Exon19 of the EGFR gene. She was diagnosed as stage IVA (cT1cN3M1b) pulmonary adenocarcinoma, and the chemotherapy with afatinib maleate (EGFR tyrosine kinase blocker) was started. At the same time, alfacalcidol was prescribed for osteomalacia. After 5 months, the primary tumor and metastatic lesions are gradually shrinking. The bone metabolism is almost normalized, and FGF23 level is markedly decreased (42 pg/ml). At present, the arthralgia is ameliorated and controlled with minimal dose of analgesics. This is a rare case of TIO associated with pulmonary adenocarcinoma. The DOTATOC-PET/CT was an effective modality for diagnosis.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
A case report: FGF23-related tumor-induced osteomalacia in a patient with pulmonary adenocarcinoma
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by the abnormal production of fibroblast growth factor 23 (FGF23) in the tumor. Here we report a case of TIO with pulmonary adenocarcinoma. A 61-year old woman was referred to our hospital. She was suffering from severe polyarthralgia and bilateral limb weakness. Her blood chemistry revealed high alkaline phosphatase, low phosphate, low calcium, and low 1,25-(OH)2D3. Bone-scintigraphy revealed multiple accumulations in femoral neck, sacrum, 1st rib, sacroiliac joints and many other joints, suggesting small fractures and systemic arthritis. Endocrinological analyses exhibited elevated iPTH and markedly high FGF23 level of 3900 pg/ml (reference: 14.7–40.5 pg/ml). These findings suggest that the FGF23-producing tumor of uncertain location induced osteomalacia in this patient. DOTATOC-PET/CT showed a major uptake in a nodular lesion of the left lung and several minor uptakes in the supraclavicular, hilar and mediastinal lymph nodes. An ultrasound-guided fine needle aspiration biopsy of the left supraclavicular lymph node was performed and the histological diagnosis was metastatic adenocarcinoma. PNA-LNA PCR clamp analysis of the biopsy specimen detected a mutation in Exon19 of the EGFR gene. She was diagnosed as stage IVA (cT1cN3M1b) pulmonary adenocarcinoma, and the chemotherapy with afatinib maleate (EGFR tyrosine kinase blocker) was started. At the same time, alfacalcidol was prescribed for osteomalacia. After 5 months, the primary tumor and metastatic lesions are gradually shrinking. The bone metabolism is almost normalized, and FGF23 level is markedly decreased (42 pg/ml). At present, the arthralgia is ameliorated and controlled with minimal dose of analgesics. This is a rare case of TIO associated with pulmonary adenocarcinoma. The DOTATOC-PET/CT was an effective modality for diagnosis.
- Open Access
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
Role of endogenous ACTH on circadian aldosterone rhythm in patients with primary aldosteronism
Endocrine Connections 2014 3 173–179. DOI: 10.1530/EC-14-0086
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
Open AccessRole of endogenous ACTH on circadian aldosterone rhythm in patients with primary aldosteronism
Endocrine Connections 2014 3 173–179. DOI: 10.1530/EC-14-0086
- Open Access
- 27 May 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 10554
The Local CNP/GC-B system in growth plate is responsible for physiological endochondral bone growth
Recent studies revealed C-type natriuretic peptide (CNP) and its receptor, guanylyl cyclase-B (GC-B) are potent stimulators of endochondral bone growth. As they exist ubiquitously in body, we investigated the physiological role of the local CNP/GC-B in the growth plate on bone growth using cartilage-specific knockout mice. Bones were severely shorter in cartilage-specific CNP or GC-B knockout mice and the extent was almost the same as that in respective systemic knockout mice. Cartilage-specific GC-B knockout mice were shorter than cartilage-specific CNP knockout mice. Hypertrophic chondrocyte layer of the growth plate was drastically reduced and proliferative chondrocyte layer, along with the proliferation of chondrocytes there, was moderately reduced in either cartilage-specific knockout mice. The survival rate of cartilage-specific CNP knockout mice was comparable to that of systemic CNP knockout mice. The local CNP/GC-B system in growth plate is responsible for physiological endochondral bone growth and might further affect mortality via unknown mechanisms.
- 27 May 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 10554
Open AccessThe Local CNP/GC-B system in growth plate is responsible for physiological endochondral bone growth
Recent studies revealed C-type natriuretic peptide (CNP) and its receptor, guanylyl cyclase-B (GC-B) are potent stimulators of endochondral bone growth. As they exist ubiquitously in body, we investigated the physiological role of the local CNP/GC-B in the growth plate on bone growth using cartilage-specific knockout mice. Bones were severely shorter in cartilage-specific CNP or GC-B knockout mice and the extent was almost the same as that in respective systemic knockout mice. Cartilage-specific GC-B knockout mice were shorter than cartilage-specific CNP knockout mice. Hypertrophic chondrocyte layer of the growth plate was drastically reduced and proliferative chondrocyte layer, along with the proliferation of chondrocytes there, was moderately reduced in either cartilage-specific knockout mice. The survival rate of cartilage-specific CNP knockout mice was comparable to that of systemic CNP knockout mice. The local CNP/GC-B system in growth plate is responsible for physiological endochondral bone growth and might further affect mortality via unknown mechanisms.
- Open Access
- 1 January 2015
- Published by Springer Nature
- p. 177-186
Translational Research of the Activation of the C-Type Natriuretic Peptide (CNP)-Guanylyl Cyclase-B Pathway for Skeletal Dysplasia
- 1 January 2015
- Published by Springer Nature
- p. 177-186
Open AccessTranslational Research of the Activation of the C-Type Natriuretic Peptide (CNP)-Guanylyl Cyclase-B Pathway for Skeletal Dysplasia
- 5 March 2014
- Published by BMJ in BMJ Case Reports
- Vol. 2014
Voriconazole-induced periostitis in a patient with overlap syndromes
A 52-year-old woman with overlap syndrome and interstitial pneumonia underwent immunosuppressive therapy and she was suspected to suffer from pulmonary aspergillosis. Oral voriconazole was initiated, and a rapid elevation of alkaline phosphatase (ALP) occurred after 4 weeks. After 2 months, the patient presented diffuse pain in bilateral skeletal regions, and bone scintigraphy revealed bilateral multiple areas of increased radiotracer uptake. We suspected the skeletal involvement as voriconazole-induced periostitis. Actually, the plasma fluoride level was increased. Voriconazole was replaced with itraconazole, and after 3 weeks, the patient stopped complaining of bone pain concomitant with the decrease in ALP. Voriconazole-induced periostitis is a rare condition but had previously been reported in solid organ or patients with bone marrow transplant who received a long-term voriconazole therapy. Our present case is distinctive of previous ones, because it occurred in a patient with connective tissue disease which had its rapid progression.
- 5 March 2014
- Published by BMJ in BMJ Case Reports
- Vol. 2014
Voriconazole-induced periostitis in a patient with overlap syndromes
A 52-year-old woman with overlap syndrome and interstitial pneumonia underwent immunosuppressive therapy and she was suspected to suffer from pulmonary aspergillosis. Oral voriconazole was initiated, and a rapid elevation of alkaline phosphatase (ALP) occurred after 4 weeks. After 2 months, the patient presented diffuse pain in bilateral skeletal regions, and bone scintigraphy revealed bilateral multiple areas of increased radiotracer uptake. We suspected the skeletal involvement as voriconazole-induced periostitis. Actually, the plasma fluoride level was increased. Voriconazole was replaced with itraconazole, and after 3 weeks, the patient stopped complaining of bone pain concomitant with the decrease in ALP. Voriconazole-induced periostitis is a rare condition but had previously been reported in solid organ or patients with bone marrow transplant who received a long-term voriconazole therapy. Our present case is distinctive of previous ones, because it occurred in a patient with connective tissue disease which had its rapid progression.
- 31 October 2012
- Published by SAGE Publications in Journal of Dental Research
- Vol. 92 (1) , 58-64
The Effects of C-type Natriuretic Peptide on Craniofacial Skeletogenesis
C-type natriuretic peptide (CNP) is a potent stimulator of long bone and vertebral development via endochondral ossification. In the present study, we investigated the effects of CNP on craniofacial skeletogenesis, which consists of both endochondral and membranous ossification. Morphometric analyses of crania from CNP knockout and transgenic mice revealed that CNP stimulates longitudinal growth along the cranial length, but does not regulate cranial width. CNP markedly increased the length of spheno-occipital synchondrosis in fetal murine organ cultures, and the thickness of cultured murine chondrocytes from the spheno-occipital synchondrosis or nasal septum, resulting in the stimulation of longitudinal cranial growth. Mandibular growth includes endochondral and membranous ossification; although CNP stimulated endochondral bone growth of condylar cartilage in cultured fetal murine mandibles, differences in the lengths of the lower jaw between CNP knockout or transgenic mice and wild-type mice were smaller than those observed for the lengths of the upper jaw. These results indicate that CNP primarily stimulates endochondral ossification in the craniofacial region and is crucial for midfacial skeletogenesis.
- 31 October 2012
- Published by SAGE Publications in Journal of Dental Research
- Vol. 92 (1) , 58-64
The Effects of C-type Natriuretic Peptide on Craniofacial Skeletogenesis
C-type natriuretic peptide (CNP) is a potent stimulator of long bone and vertebral development via endochondral ossification. In the present study, we investigated the effects of CNP on craniofacial skeletogenesis, which consists of both endochondral and membranous ossification. Morphometric analyses of crania from CNP knockout and transgenic mice revealed that CNP stimulates longitudinal growth along the cranial length, but does not regulate cranial width. CNP markedly increased the length of spheno-occipital synchondrosis in fetal murine organ cultures, and the thickness of cultured murine chondrocytes from the spheno-occipital synchondrosis or nasal septum, resulting in the stimulation of longitudinal cranial growth. Mandibular growth includes endochondral and membranous ossification; although CNP stimulated endochondral bone growth of condylar cartilage in cultured fetal murine mandibles, differences in the lengths of the lower jaw between CNP knockout or transgenic mice and wild-type mice were smaller than those observed for the lengths of the upper jaw. These results indicate that CNP primarily stimulates endochondral ossification in the craniofacial region and is crucial for midfacial skeletogenesis.
- 25 January 2012
- Published by Springer Nature in Calcified Tissue International
- Vol. 90 (4) , 307-318
Skeletal Analysis of the Long Bone Abnormality (lbab/lbab) Mouse, A Novel Chondrodysplastic C-Type Natriuretic Peptide Mutant
Long bone abnormality (lbab/lbab) is a strain of dwarf mice. Recent studies revealed that the phenotype is caused by a spontaneous mutation in the Nppc gene, which encodes mouse C-type natriuretic peptide (CNP). In this study, we analyzed the chondrodysplastic skeletal phenotype of lbab/lbab mice. At birth, lbab/lbab mice are only slightly shorter than their wild-type littermates. Nevertheless, lbab/lbab mice do not undergo a growth spurt, and their final body and bone lengths are only ~60% of those of wild-type mice. Histological analysis revealed that the growth plate in lbab/lbab mice, especially the hypertrophic chondrocyte layer, was significantly thinner than in wild-type mice. Overexpression of CNP in the cartilage of lbab/lbab mice restored their thinned growth plate, followed by the complete rescue of their impaired endochondral bone growth. Furthermore, the bone volume in lbab/lbab mouse was severely decreased and was recovered by CNP overexpression. On the other hand, the thickness of the growth plate of lbab/+ mice was not different from that of wild-type mice; accordingly, impaired endochondral bone growth was not observed in lbab/+ mice. In organ culture experiments, tibial explants from fetal lbab/lbab mice were significantly shorter than those from lbab/+ mice and elongated by addition of 10−7 M CNP to the same extent as lbab/+ tibiae treated with the same dose of CNP. These results demonstrate that lbab/lbab is a novel mouse model of chondrodysplasia caused by insufficient CNP action on endochondral ossification.
- 25 January 2012
- Published by Springer Nature in Calcified Tissue International
- Vol. 90 (4) , 307-318
Skeletal Analysis of the Long Bone Abnormality (lbab/lbab) Mouse, A Novel Chondrodysplastic C-Type Natriuretic Peptide Mutant
Long bone abnormality (lbab/lbab) is a strain of dwarf mice. Recent studies revealed that the phenotype is caused by a spontaneous mutation in the Nppc gene, which encodes mouse C-type natriuretic peptide (CNP). In this study, we analyzed the chondrodysplastic skeletal phenotype of lbab/lbab mice. At birth, lbab/lbab mice are only slightly shorter than their wild-type littermates. Nevertheless, lbab/lbab mice do not undergo a growth spurt, and their final body and bone lengths are only ~60% of those of wild-type mice. Histological analysis revealed that the growth plate in lbab/lbab mice, especially the hypertrophic chondrocyte layer, was significantly thinner than in wild-type mice. Overexpression of CNP in the cartilage of lbab/lbab mice restored their thinned growth plate, followed by the complete rescue of their impaired endochondral bone growth. Furthermore, the bone volume in lbab/lbab mouse was severely decreased and was recovered by CNP overexpression. On the other hand, the thickness of the growth plate of lbab/+ mice was not different from that of wild-type mice; accordingly, impaired endochondral bone growth was not observed in lbab/+ mice. In organ culture experiments, tibial explants from fetal lbab/lbab mice were significantly shorter than those from lbab/+ mice and elongated by addition of 10−7 M CNP to the same extent as lbab/+ tibiae treated with the same dose of CNP. These results demonstrate that lbab/lbab is a novel mouse model of chondrodysplasia caused by insufficient CNP action on endochondral ossification.
- 1 January 2012
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 101 (Suppl) , 115b
4) Translational Research of Endocrinology and Metabolism
- 1 January 2012
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 101 (Suppl) , 115b
4) Translational Research of Endocrinology and Metabolism
- 1 January 2012
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 101 (9) , 2552-2562
4) Translational Research of Endocrinology and Metabolism
- 1 January 2012
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 101 (9) , 2552-2562
4) Translational Research of Endocrinology and Metabolism
- 1 August 2010
- Vol. 20 (8) , 1212-8
[Genetic basis for skeletal disease. CNP therapy for achondroplasia].
By using transgenic and knockout mice, we have elucidated that C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth. Furthermore, loss-of-function mutations in the gene coding for guanylyl cyclase-B (GC-B) , the specific receptor for CNP, have been proved to cause impaired skeletal growth in humans. Following these results, we have started to translate the stimulatory effect of CNP on endochondral bone growth into the therapy for patients with achondroplasia, and have shown that targeted overexpression of CNP in cartilage or systemic administration of CNP reverses the impaired skeletal growth of mice model of achondroplasia.
- 1 August 2010
- Vol. 20 (8) , 1212-8
[Genetic basis for skeletal disease. CNP therapy for achondroplasia].
By using transgenic and knockout mice, we have elucidated that C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth. Furthermore, loss-of-function mutations in the gene coding for guanylyl cyclase-B (GC-B) , the specific receptor for CNP, have been proved to cause impaired skeletal growth in humans. Following these results, we have started to translate the stimulatory effect of CNP on endochondral bone growth into the therapy for patients with achondroplasia, and have shown that targeted overexpression of CNP in cartilage or systemic administration of CNP reverses the impaired skeletal growth of mice model of achondroplasia.